Agenus/AGEN

$5.73

15.29%
-
1D1W1MYTD1YMAX

About Agenus

Agenus Inc. is an immuno-oncology (I-O) company targeting cancer and infectious diseases with a pipeline of immunological agents. It is specialized in developing therapies to activate the body's immune system against cancer and infections. Its pipeline includes immune-modulatory antibodies, adoptive cell therapies (via MiNK Therapeutics, Inc.), and vaccine adjuvants (via SaponiQx, Inc.). Its primary focus is I-O, and its diverse pipeline is supported by its in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. Its most advanced antibody candidates are botensilimab (a multifunctional immune cell activator and human Fc-enhanced cytotoxic T-lymphocyte antigen 4 (CTLA-4) blocking antibody (AGEN1811)) and balstilimab (a programmed death receptor-1 (PD-1) blocking antibody). Its pipeline includes several classes of immunotherapies: checkpoint inhibitors, immune activators, and tumor microenvironment conditioning agents.

Ticker

AGEN

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology & Drugs

CEO

Garo Armen

Employees

389

Headquarters

Lexington, United States

Agenus Metrics

BasicAdvanced
$113.11M
Market cap
-
P/E ratio
-$0.70
EPS
1.43
Beta
-
Dividend rate
$113.11M
1.43078
$42.60
$5.38
597.45K
0.439
-1.64%
-70.78%
-194.81%
0.724
59.46%
10.37%
21.03%

What the Analysts think about Agenus

Analyst Ratings

Majority rating from 5 analysts.
Buy

Price Targets

Average projection from 4 analysts.
1,448.87% upside
High $160.00
Low $35.00
$5.73
Current price
$88.75
Average price target

Agenus Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
-55.13% profit margin
QuarterlyAnnual
Q4 23
QoQ growth
Revenue
$83.8M
244.86%
Net income
$-46.2M
-25.72%
Profit margin
-55.13%
-78.46%

Agenus Earnings Performance

Earnings per share (EPS)

Company profitability
Missed by 147.62%
QuarterlyAnnual
Q1 23
Q2 23
Q3 23
Q4 23
Q1 24
Actual
-$0.22
-$0.20
-$0.16
-$0.13
-
Expected
-$0.21
-$0.20
-$0.19
-$0.05
-$2.83
Surprise
4.76%
0.84%
-16.67%
147.62%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

FAQs

What’s the current market cap for Agenus stock?

Agenus (AGEN) has a market cap of $113.11M as of April 20, 2024.

What is the P/E ratio for Agenus stock?

The price to earnings (P/E) ratio for Agenus (AGEN) stock is 0 as of April 20, 2024.

Does Agenus stock pay dividends?

No, Agenus (AGEN) stock does not pay dividends to its shareholders as of April 20, 2024.

When is the next Agenus dividend payment date?

Agenus (AGEN) stock does not pay dividends to its shareholders.

What is the beta indicator for Agenus?

Agenus (AGEN) has a beta rating of 1.43. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.

What is the Agenus stock price target?

The target price for Agenus (AGEN) stock is $88.75, which is 1571.37% above the current price of $5.31. This is an average based on projections from 4 analysts, and represents their view of what the stock price could be in 12 or 18 months. This should not be seen as investment advice - Lightyear does not carry out investment research.

Buy or sell Agenus stock

Buy or sell Agenus stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing